Granisol

Chemotherapy, Operative Surgery, Nausea + 1 more
Treatment
3 FDA approvals
20 Active Studies for Granisol

What is Granisol

GranisetronThe Generic name of this drug
Treatment SummaryOndansetron is a medication used to prevent nausea and vomiting caused by chemotherapy. It works by blocking serotonin receptors in the body, helping to reduce the feeling of nausea.
Kytrilis the brand name
Granisol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Kytril
Granisetron
1993
63

Approved as Treatment by the FDA

Granisetron, also known as Kytril, is approved by the FDA for 3 uses such as Nausea and vomiting and Nausea .
Nausea and vomiting
Nausea
Chemotherapy

Effectiveness

How Granisol Affects PatientsGranisetron is a drug that blocks serotonin type 3 (5-HT<sub>3</sub>) receptors. It does not have any effect on other serotonin receptors, or on other types of receptors. In studies, it has not impacted blood pressure, heart rate, or ECG readings. This drug is similar to ondansetron, which also blocks 5-HT<sub>3</sub> receptors. When certain drugs are taken, they release serotonin from cells in the small intestine. This serotonin then stimulates nerve receptors in the brain, which can cause nausea and vomiting. Granisetron works by blocking these
How Granisol works in the bodyGranisetron stops the vomiting center in your brain from being stimulated. It does this by blocking certain receptors that are found in the vomiting center and in your gastrointestinal tract. This stops signals from your body to the vomiting center that would normally cause you to vomit.

When to interrupt dosage

The recommended dosage of Granisol is contingent upon the diagnosed condition, such as Nausea, Radiation Therapy and Operative Surgery. The amount of dosage is contingent upon the technique of administration (e.g. Solution - Oral or Injection, solution) as recorded in the following table.
Condition
Dosage
Administration
Operative Surgery
, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL
, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Injection - Subcutaneous, Tablet - Oral, Solution - Oral, Solution - Intravenous, Subcutaneous
Radiation Therapy
, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL
, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Injection - Subcutaneous, Tablet - Oral, Solution - Oral, Solution - Intravenous, Subcutaneous
Chemotherapy
, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL
, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Injection - Subcutaneous, Tablet - Oral, Solution - Oral, Solution - Intravenous, Subcutaneous
Nausea
, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL
, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Injection - Subcutaneous, Tablet - Oral, Solution - Oral, Solution - Intravenous, Subcutaneous

Warnings

There are 20 known major drug interactions with Granisol.
Common Granisol Drug Interactions
Drug Name
Risk Level
Description
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Granisetron is combined with Anagrelide.
Apomorphine
Major
The risk or severity of hypotension can be increased when Granisetron is combined with Apomorphine.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Granisetron is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Granisetron is combined with Artemether.
Asenapine
Major
The risk or severity of QTc prolongation can be increased when Granisetron is combined with Asenapine.
Granisol Toxicity & Overdose RiskThe lowest toxic dose of the drug in rats has been found to be greater than 2000mg/kg when taken orally.

Granisol Novel Uses: Which Conditions Have a Clinical Trial Featuring Granisol?

85 active clinical trials are currently underway to ascertain the efficacy of Granisol in alleviating Nausea, Operative Surgery and Radiation Therapy.
Condition
Clinical Trials
Trial Phases
Operative Surgery
75 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2, Early Phase 1
Radiation Therapy
4 Actively Recruiting
Not Applicable, Phase 3
Nausea
0 Actively Recruiting
Chemotherapy
4 Actively Recruiting
Phase 1, Phase 3, Not Applicable

Patient Q&A Section about granisol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Granisol

Image of Washington University / Barnes Jewish Hospital in St Louis, United States.

AI-Driven Clinical Decision Support for Surgery

18+
All Sexes
St Louis, MO
20 million patients have surgery in the United States every year, with approximately 1 million of those patients requiring life-saving blood transfusion. Presurgical preparation for transfusion is important to allow for safe and timely transfusion during surgery; however, excessive preparation is unfortunately common, costly, and contributes to blood waste. This study aims to evaluate an intelligent clinical decision support system that helps clinicians prepare blood for patients who are likely to need it, while avoiding excessive preparation for patients who don't, potentially improving patient safety while reducing blood waste and healthcare costs.
Recruiting
Has No Placebo
Washington University / Barnes Jewish Hospital
Image of UPMC Hillman Cancer Center in Pittsburgh, United States.

Mobile App for Cancer

18+
All Sexes
Pittsburgh, PA
The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving chemotherapy. The main questions it aims to answer are: * Is the mobile application feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment? Participants will: * Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * Complete daily symptom ratings via study application. * Wear a Fitbit activity tracker for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study. * Optional: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).
Waitlist Available
Has No Placebo
UPMC Hillman Cancer CenterCarissa A Low
Image of UPMC Shadyside Hospital in Pittsburgh, United States.

Bright Green Light Therapy for Postoperative Pain

18+
All Sexes
Pittsburgh, PA
This is an unblinded, parallel group randomized controlled trial to evaluate bright green light as an adjunct therapy after surgery at UPMC Shadyside. The primary outcome measure will be pain intensity with secondary outcome measures including opioid requirements, sleep quality, mood, and overall post-operative recovery. Specific aims/hypotheses for this study are as follows: Aim 1: To assess bright green light therapy's potential as a complementary post-operative analgesic strategy in patients recovering from surgery Hypothesis 1: Participants exposed to bright green light, in comparison to dim white (ambient) light, will have improved postoperative pain scores and lower opioid use. Aim 2: To examine the impact of bright green light therapy on patient-centered measures of post-operative recovery that may be related to improved circadian function. Hypothesis 2: Participants exposed to bright green light, in comparison to dim white (ambient) light, will have improved quality of post-operative recovery, enhanced sleep, and reduced anxiety and depression.
Waitlist Available
Has No Placebo
UPMC Shadyside HospitalRebecca Kotcher, MD
Have you considered Granisol clinical trials? We made a collection of clinical trials featuring Granisol, we think they might fit your search criteria.Go to Trials
Image of Nationwide Children's Hospital in Columbus, United States.

Surface Electromyography for Surgery

No minimum age - 21
All Sexes
Columbus, OH
The investigators are studying a type of technology that is already used called surface electromyography (EMG). This measures and records electrical activity using sensor stickers in a non-invasive way. The purpose of this study is to use a prototype/test surface EMG machine to measure how well regional anesthesia (nerve block) is working. This device is non-invasive and being used for research use as an unapproved medical device. The information may teach us how to give nerve blocks more safely and effectively. Study participation: Subjects having surgery will have the surface EMG sensor stickers placed on their arms or legs before surgery. These will stay on during surgery and for part of recovery. Study visits: The study will consist of 1 visit that starts in the pre-operative area, through the surgery, and for part of recovery time after surgery.
Waitlist Available
Has No Placebo
Nationwide Children's HospitalGrant Heydinger, MD
Have you considered Granisol clinical trials? We made a collection of clinical trials featuring Granisol, we think they might fit your search criteria.Go to Trials
Image of UC Davis Dermatology in Sacramento, United States.

Ethyl Chloride Spray for Pain Reduction in Surgery

18+
All Sexes
Sacramento, CA
Fear of needles is a well-documented issue that affects many patients. This fear may cause significant anxiety in various medical situations, including in the dermatology office 1. If not properly managed, needle phobia can persist, affecting a patient's experience during each visit. This effect may compound and lead to avoidance behaviors that can delay necessary treatments 2. This issue is particularly relevant in a Mohs micrographic surgery (MMS) clinic where each patient experiences several painful needle injections before the day is over. Ethyl chloride is gaining popularity among dermatologists for its routine use in clinical practice due to its anesthetic and antiseptic properties, especially as a pre-injection agent. Research indicates that cryotherapy or pre-cooling the skin before administering a local anesthetic may offer benefits over topical anesthetics, such as enhanced pain relief, quicker onset, and better patient compliance 3,4. However, to our knowledge, no studies have specifically examined the effectiveness of pre-cooling with ethyl chloride prior to Mohs micrographic surgery. To address this gap, we're conducting a trial aimed at evaluating the impact of pre-cooling with ethyl chloride on pain perception in adult patients undergoing Mohs micrographic surgery with local anesthetic injections. The trial is a single-center, split-body study. The split-body design will involve dividing the surgical site into two equal halves, with one half (right side relative to patient) designated as the treatment side (receiving ethyl chloride spray prior to lidocaine injection) and the other as the control side (no ethyl chloride spray prior to injection). During the procedure, the participant will be asked to rate the pain associated with the needle injection AND the pain from infiltration of anesthetic from each side of the wound using the visual analog scale (VAS) scoring system (1 = no pain, 10 = most amount of pain possible). The results of the study will help us better understand how to mitigate pain and anxiety for patients requiring MMS.
Phase < 1
Recruiting
UC Davis Dermatology
Image of CHU de Québec-Université Laval (Hôpital de l'Enfant-Jésus) in Québec, Canada.

Lidocaine + Dexmedetomidine for Surgery Outcomes

18+
All Sexes
Québec, Canada
Up to 40% of patients experience suboptimal recovery in the days following major surgery, limiting their return to functional independence. Few preventive interventions exist, but intravenous dexmedetomidine and lidocaine administered during general anesthesia represent simple strategies that may significantly impact recovery and other patient-centred outcomes after surgery. The goal of this pilot trial is to determine the feasibility of conducting a phase 3 pragmatic adaptive multicentre trial to evaluate the impact of dexmedetomidine and lidocaine administered during major non-cardiac surgery on patient-centred outcomes.
Recruiting
Has No Placebo
CHU de Québec-Université Laval (Hôpital de l'Enfant-Jésus)Michael Verret, MD PhD FRCPC
Image of University Health Network in Toronto, Canada.

Sleep Prehabilitation for Surgery

18+
All Sexes
Toronto, Canada
The goal of this clinical trial is to learn if changing sleep behaviour can improve sleep health in patients undergoing prehabilitation before elective surgery. Prehabilitation is the use of exercise, nutrition, and psychological support before surgery to improve recovery from surgery. The main questions it aims to answer are: Does changing sleep behaviour improve sleep before surgery? Does changing sleep behaviour improve recovery after surgery? Researchers will compare participants who receive sleep support with participants who do not receive sleep support to see if it improves sleep health and recovery from surgery. Participants will be asked to attend 4 meetings with the research team to learn how they can improve their sleep. They will use questionnaires, a diary, and a wearable tracker to record their sleep.
Recruiting
Has No Placebo
University Health NetworkIan Randall, MD
Have you considered Granisol clinical trials? We made a collection of clinical trials featuring Granisol, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security